JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zalutsky, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zalutsky, M. R.
Journal of Nuclear Medicine Vol. 46 No. 1 (Suppl) 151S-156S
© 2005 by Society of Nuclear Medicine

Current Status of Therapy of Solid Tumors: Brain Tumor Therapy

Michael R. Zalutsky, PhD

Departments of Radiology and Biomedical Engineering, Duke University Medical Center, Durham, North Carolina

Treatment of malignant brain tumors with conventional approaches is largely unsuccessful because curative doses generally cannot be delivered without excessive toxicity to normal brain. Radioimmunotherapy is emerging as an attractive alternative for glioma therapy because of the potential for more selectively irradiating tumor cells while sparing normal tissues. Several institutions are engaged in phase I and phase II trials investigating the therapeutic potential of monoclonal antibodies (mAbs) labeled with the ß-emitters 131I and 90Y and the {alpha}-emitter 211At in patients with recurrent and newly diagnosed brain tumors. The current status of these trials will be discussed with regard to efficacy, toxicity, and future directions.

Key Words: brain tumor • glioma • 211At • radionuclide therapy • 131I




This article has been cited by other articles:


Home page
 JNMHome page
S. Samnick, B. F. Romeike, T. Lehmann, I. Israel, C. Rube, A. Mautes, C. Reiners, and C.-M. Kirsch
Efficacy of Systemic Radionuclide Therapy with p-131I-Iodo-L-Phenylalanine Combined with External Beam Photon Irradiation in Treating Malignant Gliomas
J. Nucl. Med., December 1, 2009; 50(12): 2025 - 2032.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
H. Sontheimer
An Unexpected Role for Ion Channels in Brain Tumor Metastasis
Exp Biol Med, July 1, 2008; 233(7): 779 - 791.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Back, H. Andersson, C. R. Divgi, R. Hultborn, H. Jensen, S. Lindegren, S. Palm, and L. Jacobsson
211At Radioimmunotherapy of Subcutaneous Human Ovarian Cancer Xenografts: Evaluation of Relative Biologic Effectiveness of an {alpha}-Emitter In Vivo
J. Nucl. Med., December 1, 2005; 46(12): 2061 - 2067.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Miao, M. Hylarides, D. R. Fisher, T. Shelton, H. Moore, D. W. Wester, A. R. Fritzberg, C. T. Winkelmann, T. Hoffman, and T. P. Quinn
Melanoma Therapy via Peptide-Targeted {alpha}-Radiation
Clin. Cancer Res., August 1, 2005; 11(15): 5616 - 5621.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.